U.S. Restricted Access Barrier System Market Size, Share & Trends Analysis Report By Application (Pharmaceutical, Chemical Manufacturing, Medical), And Segment Forecasts, 2020 - 2028
U.S. Restricted Access Barrier System Market Growth & Trends
The U.S. restricted access barrier system market size is expected to reach USD 249.4 million by 2028. It is expected to expand at a CAGR of 4.7% from 2020 to 2028. The market is primarily driven by the growth of the biotechnology industry in the U.S. due to technological advancements, an increasing number of small-scale biopharma companies, and rising investments in research.
Technological breakthroughs in biopharmaceutical and biotechnology manufacturing are expected to surge the market growth over the forecast period. The demand for modular equipment having the ability to reduce the time required for drug production and minimize the overall production cost is anticipated to provide a major boost to the market growth in the U.S.
The COVID-19 pandemic has reinstated the significance of collaborations; many life science companies are partnering among themselves to enhance R&D in the field of biotechnology. The pandemic has accelerated the need for sustainable development, energy conservation, and green pharmaceutical manufacturing, thereby influencing product development in the restricted access barrier systems (RABS) market.
A growing trend of contract development and manufacturing organization (CDMO) for aseptic manufacturing is expected to augment the demand for RABS. Contract manufacturers such as Aenova Group, DPT Laboratories, and Recipharm AB are focusing on new contracts in the U.S., in turn, positively impacting the market growth.
U.S. Restricted Access Barrier System Market Report Highlights
• The pharmaceutical application segment accounted for the largest share of 64.5% in 2020 owing to the growing pharmaceutical industry in the U.S., coupled with advantages such as a faster changeover process and easy handling
• The medical application segment is expected to expand at a CAGR of 3.9% from 2020 to 2028. This is attributed to the growing penetration of RABS in this segment owing to its ability to provide septic safety in the critical zone and flexibility for interventions
• The U.S. government is aiming to reduce the reliance on drugs manufactured outside the U.S. by encouraging pharmaceutical companies to set up manufacturing facilities in the U.S., in turn, augmenting the demand for RABS
• In February 2021, Comecer spA partnered with Illuminate Manufacturing Intelligence, a division of ATS (ATA.TO), to develop a production solution integrating its containment equipment portfolio in line with Industry 4.0